BlackRock is an investment management firm. The company provides a range of investment and technology services to institutional and retail clients worldwide. Products are provided directly and through intermediaries in a variety of vehicles, including open-end and closed-end mutual funds, iShares? exchange-traded funds, separate accounts, collective investment trusts and other pooled investment vehicles. The company also provides technology services, including the investment and risk management technology platform, Aladdin?, Aladdin Wealth, eFront, Cachematrix and FutureAdvisor, as well as advisory services and solutions to a base of institutional and wealth management clients.

Diodes is a manufacturer and supplier of application-specific standard products. The company's product line includes: discrete semiconductor products, which include performance Schottky rectifiers, performance Schottky diodes, Zener diodes and performance Zener diodes; analog products, which include power management devices; standard logic products including complementary metal-oxide-semiconductor devices and analog switches; multichip products and co-packaged discrete, analog and mixed-signal silicon in miniature packages; silicon and silicon epitaxial wafers used in manufacturing these products; and Frequency Control Products, which are electronic components that provide frequency references.

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of the company's proprietary PRINT? technology to transform the lives of patients. The company is focused on the development of two product candidates for which it holds commercial rights: LIQ861, which is for the treatment of pulmonary arterial hypertension, a disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death; and LIQ865, which is an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain a surgical procedure.

OncoCyte is focused on developing non-invasive molecular diagnostic tests for cancer diagnosis. The company is developing DetermaVu?, a non-invasive molecular lung cancer confirmatory diagnostic that can be administered to patients as a blood test. DetermaVu? utilizes proprietary sets of gene expression markers to help confirm whether lung nodules detected via Low Dose Computed Tomography scans, x-rays or other imaging are likely to be benign or malignant. DetermaVu? is based on the company's Immune System Interrogation approach that checks the body's immune system response to a specific disease by measuring differential RNA expression in patients with the disease versus patients without the disease.

Sensient Technologies is a manufacturer and marketer of colors, flavors and fragrances. The company's three reportable segments are: Flavors & Fragrances Group, which develops, manufactures, and supplies flavor and fragrance systems for the food, beverage, personal care, and household-products industries; Color Group, which provides natural and synthetic color systems for use in foods, beverages, pharmaceuticals, and nutraceuticals, colors and other ingredients for cosmetics; and Asia Pacific Group, which provides a range of products from its Flavors & Fragrances Group and Color Group, as well as products developed by regional technical teams to appeal to local preferences.